|
1
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 Suppl 4:S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yokoyama K, Goodwin GW, Ghomashchi F,
Glomset JA and Gelb MH: A protein geranylgeranyltransferase from
bovine brain: Implications for protein prenylation specificity.
Proc Natl Acad Sci USA. 88:pp. 5302–5306. 1991; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reid TS, Terry KL, Casey PJ and Beese LS:
Crystallographic analysis of CaaX prenyltransferases complexed with
substrates defines rules of protein substrate selectivity. J Mol
Biol. 343:417–433. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kusama T, Mukai M, Tatsuta M, Matsumoto Y,
Nakamura H and Inoue M: Selective inhibition of cancer cell
invasion by a geranylgeranyltransferase-I inhibitor. Clin Exp
Metastasis. 20:561–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun J, Qian Y, Chen Z, Marfurt J, Hamilton
AD and Sebti SM: The geranylgeranyltransferase I inhibitor GGTI-298
induces hypophosphorylation of retinoblastoma and partner switching
of cyclin-dependent kinase inhibitors. A potential mechanism for
GGTI-298 antitumor activity. J Biol Chem. 274:6930–6934. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dan HC, Jiang K, Coppola D, Hamilton A,
Nicosia SV, Sebti SM and Cheng JQ: Phosphatidylinositol-3-OH
kinase/AKT and survivin pathways as critical targets for
geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene.
23:706–715. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sonnemann J, Bumbul B and Beck JF:
Synergistic activity of the histone deacetylase inhibitor
suberoylanilide hydroxamic acid and the bisphosphonate zoledronic
acid against prostate cancer cells in vitro. Mol Cancer Ther.
6:2976–2984. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Berndt N, Hamilton AD and Sebti SM:
Targeting protein prenylation for cancer therapy. Nat Rev Cancer.
11:775–791. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
McGuire TF, Qian Y, Vogt A, Hamilton AD
and Sebti SM: Platelet-derived growth factor receptor tyrosine
phosphorylation requires protein geranylgeranylation but not
farnesylation. J Biol Chem. 271:27402–27407. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li F, Jiang Q, Shi KJ, Luo H, Yang Y and
Xu CM: RhoA modulates functional and physical interaction between
ROCK1 and Erk1/2 in selenite-induced apoptosis of leukaemia cells.
Cell Death Dis. 4:e7082013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Del Re DP, Miyamoto S and Brown JH: Focal
adhesion kinase as a RhoA-activable signaling scaffold mediating
Akt activation and cardiomyocyte protection. J Biol Chem.
283:35622–35629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Basile JR, Gavard J and Gutkind JS:
Plexin-B1 utilizes RhoA and Rho kinase to promote the
integrin-dependent activation of Akt and ERK and endothelial cell
motility. J Biol Chem. 282:34888–34895. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hebert M, Potin S, Sebbagh M, Bertoglio J,
Breard J and Hamelin J: Rho-ROCK-dependent ezrin-radixin-moesin
phosphorylation regulates Fas-mediated apoptosis in Jurkat cells. J
Immunol. 181:5963–5973. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chou TC, Motzer RJ, Tong Y and Bosl GJ:
Computerized quantitation of synergism and antagonism of taxol,
topotecan, and cisplatin against human teratocarcinoma cell growth:
A rational approach to clinical protocol design. J Natl Cancer
Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sorrentino G, Ruggeri N, Specchia V,
Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio
R, Piazza S, et al: Metabolic control of YAP and TAZ by the
mevalonate pathway. Nat Cell Biol. 16:357–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li P, Wei J and Gao X: Insulin promotes
the proliferation of human umbilical cord matrix-derived
mesenchymal stem cells by activating the Akt-Cyclin D1 axis. Stem
Cells Int. 2017:73716152017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng W, Gu L, Li X, Zheng J, Zhang Y, Duan
B, Cui J, Dong J and Du J: CD24 associates with EGFR and supports
EGF/EGFR signaling via RhoA in gastric cancer cells. J Transl Med.
14:322016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Janjigian YY, Smit EF, Groen HJ, Horn L,
Gettinger S, Camidge DR, Riely GJ, Wang B, Fu Y, Chand VK, et al:
Dual inhibition of EGFR with afatinib and cetuximab in kinase
inhibitor-resistant EGFR-mutant lung cancer with and without T790M
mutations. Cancer Discov. 4:1036–1045. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fischer OM, Hart S, Gschwind A and Ullrich
A: EGFR signal transactivation in cancer cells. Biochem Soc Trans.
31:1203–1208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song S, Honjo S, Jin J, Chang SS, Scott
AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et
al: The Hippo coactivator YAP1 mediates EGFR overexpression and
confers chemoresistance in esophageal cancer. Clin Cancer Res.
21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He C, Mao D, Hua G, Lv X, Chen X,
Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, et al: The
Hippo/YAP pathway interacts with EGFR signaling and HPV
oncoproteins to regulate cervical cancer progression. EMBO Mol Med.
7:1426–1449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chrysogelos SA and Dickson RB: EGF
receptor expression, regulation, and function in breast cancer.
Breast Cancer Res Treat. 29:29–40. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang Y, Xia H, Ge X, Chen Q, Yuan D, Chen
Q, Leng W, Chen L, Tang Q and Bi F: CD44 acts through RhoA to
regulate YAP signaling. Cell Signal. 26:2504–2513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li H, Ung CY, Ma XH, Li BW, Low BC, Cao ZW
and Chen YZ: Simulation of crosstalk between small GTPase RhoA and
EGFR-ERK signaling pathway via MEKK1. Bioinformatics. 25:358–364.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lunn JA, Wong H, Rozengurt E and Walsh JH:
Requirement of cortical actin organization for bombesin,
endothelin, and EGF receptor internalization. Am J Physiol Cell
Physiol. 279:C2019–C2027. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Asanuma K, Yanagida-Asanuma E, Faul C,
Tomino Y, Kim K and Mundel P: Synaptopodin orchestrates actin
organization and cell motility via regulation of RhoA signalling.
Nat Cell Biol. 8:485–491. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee J, Lee I, Han B, Park JO, Jang J, Park
C and Kang WK: Effect of simvastatin on cetuximab resistance in
human colorectal cancer with KRAS mutations. J Natl Cancer Inst.
103:674–688. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sebti SM and Hamilton AD:
Farnesyltransferase and geranylgeranyltransferase I inhibitors and
cancer therapy: Lessons from mechanism and bench-to-bedside
translational studies. Oncogene. 19:6584–6593. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mantha AJ, Hanson JE, Goss G, Lagarde AE,
Lorimer IA and Dimitroulakos J: Targeting the mevalonate pathway
inhibits the function of the epidermal growth factor receptor. Clin
Cancer Res. 11:2398–2407. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Niknejad N, Morley M and Dimitroulakos J:
Activation of the integrated stress response regulates
lovastatin-induced apoptosis. J Biol Chem. 282:29748–29756. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dimitroulakos J, Lorimer IA and Goss G:
Strategies to enhance epidermal growth factor inhibition: Targeting
the mevalonate pathway. Clin Cancer Res. 12:4426s–4431s. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hwang KE, Kwon SJ, Kim YS, Park DS, Kim
BR, Yoon KH, Jeong ET and Kim HR: Effect of simvastatin on the
resistance to EGFR tyrosine kinase inhibitors in a non-small cell
lung cancer with the T790M mutation of EGFR. Exp Cell Res.
323:288–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Simons K and Sampaio JL: Membrane
organization and lipid rafts. Cold Spring Harb Perspect Biol.
3:a0046972011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ernster L and Dallner G: Biochemical,
physiological and medical aspects of ubiquinone function. Biochim
Biophys Acta. 1271:195–204. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lobell RB, Liu D, Buser CA, Davide JP,
DePuy E, Hamilton K, Koblan KS, Lee Y, Mosser S, Motzel SL, et al:
Preclinical and clinical pharmacodynamic assessment of L-778,123, a
dual inhibitor of farnesyl:protein transferase and
geranylgeranyl:protein transferase type-I. Mol Cancer Ther.
1:747–758. 2002.PubMed/NCBI
|
